TY - JOUR
T1 - Hypersensitivity reactions to non-betalactam antibiotics in children
T2 - An extensive review
AU - On Behalf of Pediatric Task Force of EAACI Drug Allergy Interest Group
AU - Kuyucu, Semanur
AU - Mori, Francesca
AU - Atanaskovic-Markovic, Marina
AU - Caubet, Jean Christoph
AU - Terreehorst, Ingrid
AU - Gomes, Eva
AU - Brockow, Knut
N1 - Publisher Copyright:
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - In contrast to hypersensitivity reactions (HSRs) to β-lactam antibiotics in children, studies about HSR to non-β-lactam antibiotics (NBLAs) such as sulfonamides, macrolides, quinolones, and antituberculosis agents are scarce, and information is generally limited to case reports. The aim of this extensive review was to summarize our present knowledge on clinical characteristics, evaluation, and management of HSR to NBLAs in children based on the literature published between 1980 and 2013. NBLAs have been reported to induce a wide spectrum of HSRs from mild eruptions to severe, and sometimes fatal, systemic drug reactions, especially in some high-risk groups. The diagnosis relied upon history and remained unconfirmed by allergological tests in most of the cases. Obtaining a detailed history is valuable in the diagnosis of suspected reactions to NBLAs. Diagnostic in vivo and in vitro tests for NBLAs lack validation, which makes the diagnosis challenging. The definitive diagnosis of NBLA hypersensitivity frequently depends upon drug provocation tests. Studies including children showed that only 7.8 to 36% of suspected immediate and delayed HSRs to NBLAs could be confirmed by skin and/or provocation tests. Therefore, a standardized diagnostic approach and management strategy should be developed and employed for pediatric patients in the evaluation of suspected HSRs to NBLAs, some of which may be critical and unreplaceable in certain clinical situations.
AB - In contrast to hypersensitivity reactions (HSRs) to β-lactam antibiotics in children, studies about HSR to non-β-lactam antibiotics (NBLAs) such as sulfonamides, macrolides, quinolones, and antituberculosis agents are scarce, and information is generally limited to case reports. The aim of this extensive review was to summarize our present knowledge on clinical characteristics, evaluation, and management of HSR to NBLAs in children based on the literature published between 1980 and 2013. NBLAs have been reported to induce a wide spectrum of HSRs from mild eruptions to severe, and sometimes fatal, systemic drug reactions, especially in some high-risk groups. The diagnosis relied upon history and remained unconfirmed by allergological tests in most of the cases. Obtaining a detailed history is valuable in the diagnosis of suspected reactions to NBLAs. Diagnostic in vivo and in vitro tests for NBLAs lack validation, which makes the diagnosis challenging. The definitive diagnosis of NBLA hypersensitivity frequently depends upon drug provocation tests. Studies including children showed that only 7.8 to 36% of suspected immediate and delayed HSRs to NBLAs could be confirmed by skin and/or provocation tests. Therefore, a standardized diagnostic approach and management strategy should be developed and employed for pediatric patients in the evaluation of suspected HSRs to NBLAs, some of which may be critical and unreplaceable in certain clinical situations.
KW - Children
KW - Diagnosis
KW - Drug allergy
KW - Drug hypersensitivity
KW - Non-beta(β)lactam antibiotics
KW - Skin tests
UR - http://www.scopus.com/inward/record.url?scp=84922766297&partnerID=8YFLogxK
U2 - 10.1111/pai.12273
DO - 10.1111/pai.12273
M3 - Review article
C2 - 25201401
AN - SCOPUS:84922766297
SN - 0905-6157
VL - 25
SP - 534
EP - 543
JO - Pediatric Allergy and Immunology
JF - Pediatric Allergy and Immunology
IS - 6
ER -